Source comparison
Peptides for Bodybuilding: Comparison of Mechanisms and Clinical Evidence
GHRP-6 Ghrelin receptor agonist → pulsatile GH release IGF-1 increase 60–90%, modest LBM gain 100–300mcg 2–3x daily Increased appetite, transient cortisol spike Effective for GH optimization; appetite surge limits cut-phase use Ipamorelin Selective GHS-R1a ago
This comparison does not assign a generated winner or score.
- GHRP-6
- Ghrelin receptor agonist → pulsatile GH release
- IGF-1 increase 60–90%, modest LBM gain
- 100–300mcg 2–3x daily
- Increased appetite, transient cortisol spike
- Effective for GH optimization; appetite surge limits cut-phase use
- Ipamorelin
- Selective GHS-R1a agonist → GH pulse without ghrelin effects
- GH secretion +200–400% vs baseline
- 200–300mcg 2–3x daily
- Minimal; occasional injection site reaction
- Cleanest GH secretagogue for lean mass retention
- MK 677
- Oral GH secretagogue; 24-hour half-life
- LBM +1.1kg over 12 weeks (clinical trial)
- 12.5–25mg once daily
- Insulin resistance risk >12 weeks, water retention
- Oral convenience; requires glucose monitoring long-term
- BPC-157
- Angiogenesis + growth factor upregulation at injury sites
- 60% faster tendon healing in preclinical models
- 250–500mcg 2x daily
- Minimal documented side effects
- Strong preclinical evidence; no human RCTs yet
- TB-500
- Actin polymerization + cell migration to damaged tissue
- Accelerated soft tissue repair in animal models
- 2mg 2x weekly (loading), 2mg weekly (maintenance)
- Rare; occasional fatigue
- Mechanistically distinct from BPC-157; stacks well
- Follistatin-344
- Myostatin inhibitor → removes growth ceiling
- +25% muscle mass in gene therapy models (mice)
- 100–300mcg daily (no human dosing standard)
- Unknown; theoretical cardiac risk
- High potential, low human data; dosing precision critical